Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Iihara, J. Endo, M. Yamada, K. Kitaichi, K. Yanase, F. Kamiya, F. Ito, N. Funaguchi, Y. Ohno, S. Minatoguchi, Y. Itoh (Gifu, Japan). The antiemetic effects of oral azasetron in lung cancer patients treated with moderately emetogenic chemotherapy: Comparison with intravenous granisetron. Eur Respir J 2012; 40: Suppl. 56, 1244

Member's Comments

No comment yet.

Related content which might interest you: Dexamethasone improves antiemetic control in lung cancer patients treated with chemotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 The effectiveness of pegfilgrastim in preventing leucopenia in patients with lung cancer under chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Survival and respiratory effects in NSCLC patients after treatment with inhaled carboplatin Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006 A study of paclitaxel in two dose combinations with carboplatin in the treatment of small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001 Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 A prospective study on lung toxicity in patients treated with paclitaxel and carboplatin Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006 Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006 A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004